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The present study was carried out to investigate the  biochemical effects of 
hypolip (simvastatin) on serum total cholesterol and low density lipoprotein-
cholesterol (LDL-c) and to assess its effects on renal profile,  hematological 
and histopathological parameters.Twenty- five Wister albino rats were 
divided into five groups. Group A was fed basal diet only (control group) 
and the other four groups (B, C, D and E) were fed 1% cholesterol diet for 
two weeks to induce hypercholesterolemia. After two weeks,  groups C, D 
and E (treated groups) were orally administrated hypolip at a dose rate of 10, 
40 and 80 mg/kg Bwt respectively,for four weeks. Blood samples were 
obtained from the orbital plexus vein and collected in heparinized tubes 
every two weeks to investigate serum lipid profile, serum constituents and 
hematological parameters. Specimens from kidney, aorta, brain and intestine 
were immediately removed after the rats were slaughtered, and fixed in 10% 
neutral formalin, for histopathological investigations. 
There was a significant (P<0.05) increase in the serum total-
cholesterol and LDL-c concentrations in groups B, C, D and E compared 
with group A after two weeks. Also, there was a significant increase in body 
weights in induced hypercholesterolemic rats. Two weeks after 
administration of hypolip, there was no significant changes in serum total 
cholesterol concentration in groups C, D and E compared with group B. 
However, there was a significant decrease in LDL-c in groups D and E, 
compared with group B and a significant decrease in high density 
lipoprotein-cholesterol (HDL-c) in groups D and E and triglycerides in 
group E compared with group B. Four weeks after administration of hypolip, 
there was a significant decrease in serum total-cholesterol in groups C and D 
and a highly significant (P<0.01) decrease in group E. There was a 
 significant increase in serum HDL-c in groups D and E and a significant 
decrease in serum triglycerides in groups D and E compared with group B. 
There was a significant decrease in blood urea in groups C, D and E 
compared with group B after four weeks of administration of hypolip. There 
were no significant changes in levels of serum creatinine, potassium and 
sodium between treated groups (C, D and E) and group B throughout the 
experimental period. Hematological findings demonstrated that there were 
no significant differences in red blood cell counts between treated groups (C, 
D, and E) and group B. However, there was a significant decrease in white 
blood cell counts in group D compared with group B. Hemoglobin 
concentrations and PCV showed a significant decrease in group E compared 
with group B; but, there were no significant changes on platelets 
concentrations between treated groups (C, D and E) and group B. 
 Histopathologically, the aortal wall was thickened with                       
a precipitation of cholesterol clefts, particularly in group B. Renal tissues 
showed hemorrhage, congestion, infiltration of inflammatory cells in group 
B. In the treated groups, kidneys showed hemorrhage, segmented golmeruli 
and infiltration of inflammatory cells surrounding blood arteriole. The 
intestine showed hemorrhage, necrosis of epithelial cells, increasing number 
of goblet cells and infiltration of inflammatory cells in treated groups.  The 
brain showed congestion, vaculation, demyelation of neurons, congestion 
and infiltration of microglaial cells in treated groups. 
   ﺍﻟﻤﺴﺘﺨﻠﺹ
 ﻰـﻋﻠ( ﺍﻟﺴﻤﻔﺎﺴﺘﺎﺘﻴﻥ)  ﻬﻴﺒﻭﻟﺏﻠﻟ ﺌﻴﺔﺍﻟﺒﻴﻭﻜﻴﻤﻴﺎﺭﺎﺜﺍﻵﻲ ـﺔ ﻟﺘﻘﺼـﺫﻩ ﺍﻟﺩﺍﺭﺴـﺃﺠﺭﻴﺕ ﻫ
ﺘﺤﺩﻴﺩ ﺔ ﺍﻟﻜﺜﺎﻓﺔ ﻭﺍﻟﺠﻠﺴﺭﻴﺩﺍﺕ ﺍﻟﺜﻼﺜﻴﺔ ﻭﻔﻀﻤﻨﺨﺍﻟﻤﺭﺘﻔﻌﺔ ﻭﺍﻟ ﻗﻴﺎﺴﺎﺕ ﺍﻟﻜﻠﺴﺘﺭﻭل ﻭﺍﻟﺒﺭﻭﺘﻴﻨﺎﺕ ﺍﻟﺩﻫﻨﻴﺔ
ﻟﺨﻤﺱ  ﻤﻥ ﻨﻭﻉ ﺍﻟﺒﻴﻨﻭ ﻓﺄﺭﺍﹰ 52 ﻗﺴﻤﺕ .ﻭﺍﻟﺘﻐﻴﺭﺍﺕ ﺍﻟﻨﺴﻴﺠﻴﺔ ﻭﻅﺎﺌﻑ ﺍﻟﺩﻡﻭ ﻭﻅﺎﺌﻑ ﺍﻟﻜﻠﻲﻋﻠﻲ  ﺘﺄﺜﻴﺭﻩ
 ﺍﻟﻤﺠﻤﻭﻋﺎﺕ ﻭ( ﻤﻭﻋﺔ ﺘﺤﻜﻡﻤﺠ)ﻟﻠﻔﺌﺭﺍﻥ ﻓﻘﻁ ﺃﻋﻁﻴﺕ ﺍﻟﻭﺠﺒﺔ ﺍﻷﺴﺎﺴﻴﺔ  ، ﺍﻟﻤﺠﻤﻭﻋﺔ ﺃﻤﺠﻤﻭﻋﺎﺕ
ﻤﻥ ﻤﺴﺤﻭﻕ ﺍﻟﻜﻠﺴﺘﺭﻭل  % 1ﺃﻋﻁﻴﺕ ﺍﻟﻭﺠﺒﺔ ﺍﻷﺴﺎﺴﻴﺔ ﻤﻀﺎﻓﺎﹰ ﻟﻬﺎ   ه, ﺩ , ﺠ  ,ﺏ ﺍﻷﺭﺒﻊ ﺍﻷﺨﺭﻱ
 ﺒﻌﺩ. ﺍﻟﻜﻠﺴﺘﺭﻭل ﻓﻲ ﺩﻡ ﺍﻟﻔﺌﺭﺍﻥ ﻻﺤﺩﺍﺙ ﺯﻴﺎﺩﺓ ﻓﻲ ﺘﺭﻜﻴﺯ ﻜﺠﻡ ﻤﻥ ﺍﻟﻁﻌﺎﻡ ﻟﻤﺩﺓ ﺃﺴﺒﻭﻋﻴﻥ ﻭﺫﻟﻙﻟﻜل 
 ٠٨ , ٠٤ ,٠١ﻜﻴﺯﺍﺒﻭﺍﺴﻁﺔ ﺍﻟﻔﻡ ﺒﺘﺭ ﺒﻭﻟﺏﻫﻴﺒﻌﻘﺎﺭ   ه, ﺩ ,ﺠ  ﻤﺠﻤﻭﻋﺎﺕﺍﻟ، ﻋﻭﻟﺠﺕ ﺍﺴﺒﻭﻋﻴﻥ ﻤﻀﻲ
ﺍﻟﻭﺭﻴﺩ  ﺍﻟﻔﺌﺭﺍﻥ ﻤﻥ ﺃﺨﺫﺕ ﻋﻴﻨﺎﺕ ﺍﻟﺩﻡ ﻤﻥ .ﻟﻤﺩﺓ ﺃﺭﺒﻌﺔ ﺃﺴﺎﺒﻴﻊ ﻋﻠﻲ ﺍﻟﺘﻭﺍﻟﻲﻤﻠﺠﻡ ﻤﻥ ﻭﺯﻥ ﺍﻟﺠﺴﻡ 
ﺘﺤﺘﻭﻱ ﻋﻠﻲ ﺍﻟﻬﻴﺒﺎﺭﻴﻥ ﻜل ﺃﺴﺒﻭﻋﻴﻥ ﻟﻘﻴﺎﺱ ﺍﻟﻌﻴﻨﺎﺕ ﻓﻲ ﺍﻨﺎﺒﻴﺏ ﺍﺨﺘﺒﺎﺭ  ﺕﺜﻡ ﺠﻤﻌ ﺍﻟﺤﺠﺎﺒﻲ ﻟﻠﻌﻴﻥ
ﺔ ﺍﻟﻜﺜﺎﻓﺔ ﻭﺍﻟﺠﻠﺴﺭﻴﺩﺍﺕ ﺍﻟﺜﻼﺜﻴﺔ ﻭﻗﻴﺎﺴﺎﺕ ﺘﻔﻌﺍﻟﻤﺭﻤﻨﺨﻔﻀﺔ ﻭﺍﻟﻤﺴﺘﻭﻱ ﺍﻟﻜﻠﺴﺘﺭﻭل ﻭﺍﻟﺒﺭﻭﺘﻴﻨﺎﺕ ﺍﻟﺩﻫﻨﻴﺔ 
ﺃﻅﻬﺭﺕ .ﻤﺭﻴﻀﺔﻭﻅﺎﺌﻑ ﺍﻟﻜﻠﻲ ﻭﻭﻅﺎﺌﻑ ﺍﻟﺩﻡ، ﻭﺃﺨﺫﺕ ﺃﻴﻀﺎﹰ ﻋﻴﻨﺎﺕ ﻤﻥ ﺍﻷﻋﻀﺎﺀ ﻟﻔﺤﺹ ﺍﻷﻨﺴﺠﺔ ﺍﻟ
ﺔ ﻓﻲ ﻤﺴﺘﻭﻱ ﻜﻠﺴﺘﺭﻭل ﺍﻟﺩﻡ ﻭﺍﻟﺒﺭﻭﺘﻴﻨﺎﺕ ﺍﻟﺩﻫﻨﻴﺔ ﻤﻨﺨﻔﻀﺔ ﻌﻨﻭﻴﺯﻴﺎﺩﺓ ﻤ ﻡ ﺒﻌﺩ ﺃﺴﺒﻭﻋﻴﻥﻨﺘﺎﺌﺞ ﺘﺤﺎﻟﻴل ﺍﻟﺩ
ﺔ ﻓﻲ ﻭﺯﻥ ﺍﻟﻔﺌﺭﺍﻥ ﻌﻨﻭﻴﺯﻴﺎﺩﺓ ﻤ ﻫﻨﺎﻙﻭ ﻤﺠﻤﻭﻋﺔ ﺃﺎﻟﺒﻤﻘﺎﺭﻨﺔ   ه, ﺩ  ,  ﺠ ,ﺏ ﻓﻲ ﻤﺠﻤﻭﻋﺎﺕ ﺍﻟﻜﺜﺎﻓﺔ
  ﺃﺴﺒﻭﻋﻴﻥﻟﻤﺩﺓ  ﻫﻴﺒﻭﻟﺏﺒﻌﺩ ﺇﻋﻁﺎﺀ ﻋﻘﺎﺭ  .ﻤﺠﻤﻭﻋﺔ ﺃﺎﻟﻤﻘﺎﺭﻨﺔ ﺒ  ه, ﺩ  , ﺠ  ,ﺏ ﻟﻠﻤﺠﻤﻭﻋﺎﺕ
ﻡ ﺍﻟﺩﻤﻨﺨﻔﻀﺔ ﺍﻟﻜﺜﺎﻓﺔ ﻓﻲ ﺍﻟﺎ ﻓﻲ ﺘﺭﻜﻴﺯ ﺍﻟﺒﺭﻭﺘﻴﻨﺎﺕ ﺍﻟﺩﻫﻨﻴﺔ ﻌﻨﻭﻴﺃﻭﻀﺤﺕ ﺍﻟﻨﺘﺎﺌﺞ  ﻭﺠﻭﺩ ﻨﻘﺼﺎﻨﺎ ﻤ
ﺘﻐﻴﺭﺍﺕ ﻓﻲ ﻤﺴﺘﻭﻱ  ﺍﻟﻜﻠﺴﺘﺭﻭل  ﻭﻟﻡ ﺘﻭﺠﺩ ،ﺏ ﻤﺠﻤﻭﻋﺔﺎﻟﻤﻘﺎﺭﻨﺔ ﺒ  ه, ﺩ  , ﺠ  ﺨﺼﻭﺼﺎ ﻤﺠﻤﻭﻋﺎﺕ
ﺒﻨﻬﺎﻴﺔ ﺍﻷﺴﺒﻭﻉ ﻭ. ﺍﻟﻜﺜﺎﻓﺔ ﺃﻭ ﺍﻟﺠﻠﺴﺭﻴﺩﺍﺕ ﺍﻟﺜﻼﺜﻴﺔ ﺃﻭ ﻭﻅﺎﺌﻑ ﺍﻟﻜﻠﻲ ﺍﻟﻤﺭﺘﻔﻌﺔ ﺍﻟﺩﻫﻨﻴﺔ ﺃﻭ ﺍﻟﺒﺭﻭﺘﻴﻨﺎﺕ
    ه, ﺩ  , ﺠ   ﻠﻤﺠﻤﻭﻋﺎﺕﻟ ﻓﻲ ﺍﻟﺩﻡ  ﻠﻜﻠﺴﺘﺭﻭلﻟ ﻌﻨﻭﻱﻤ ﺍﻨﺨﻔﺎﺽ ﺤﺩﺙ ﻫﻴﺒﻭﻟﺏ ﻹﻋﻁﺎﺀﺍﻟﺭﺍﺒﻊ 
ﺩ، ﻤﺠﻤﻭﻋﺘﻲ  ﺔﻴﺍﻟﺠﻠﺴﺭﻴﺩﺍﺕ ﺍﻟﺜﻼﺜ ﻭ ﻤﻨﺨﻔﻀﺔ ﺍﻟﻜﺜﺎﻓﺔﺍﻟﺔ ﺍﻟﺒﺭﻭﺘﻴﻨﺎﺕ ﺍﻟﺩﻫﻨﻴﻓﻲ ﻭ ﻤﻘﺎﺭﻨﺔ ﺒﺎﻟﻤﺠﻤﻭﻋﺔ ﺏ
ﻤﻘﺎﺭﻨﺔ   ه, ﺩ ﻤﺠﻤﻭﻋﺘﻲ ﻓﻲﺔ ﻌﻨﻭﻴﻤ ﺯﻴﺎﺩﺓ ﺍﻟﻜﺜﺎﻓﺔ ﺍﻟﻤﺭﺘﻔﻌﺔﺴﺠﻠﺕ ﺍﻟﺒﺭﻭﺘﻴﻨﺎﺕ ﺍﻟﺩﻫﻨﻴﺔ  ﺒﻴﻨﻤﺎ .ه
ﻓﻲ ﻤﺠﻤﻭﻉ ﻜﺭﻴﺎﺕ ﺍﻟﺩﻡ ﺍﻟﺤﻤﺭﺍﺀ  ﻤﻌﻨﻭﻱﺃﻅﻬﺭﺕ ﻨﺘﺎﺌﺞ ﻭﻅﺎﺌﻑ ﺍﻟﺩﻡ ﻋﺩﻡ ﻭﺠﻭﺩ ﺘﻐﻴﺭ .ﺒﺎﻟﻤﺠﻤﻭﻋﺔ ﺏ
ﺍﻟﻨﺴﺒﺔ ﺍﻟﻤﺌﻭﻴﺔ ﻭ ﺴﺠل ﺘﺭﻜﻴﺯ ﺍﻟﻬﻴﻤﻭﻗﻠﻭﺒﻴﻥ .ﻤﺠﻤﻭﻋﺔ ﺏﺍﻟﻭ  ه, ﺩ  , ﺠ  ﺒﻴﻥ ﺍﻟﻤﺠﻤﻭﻋﺎﺕ ﺍﻟﻤﻌﺎﻟﺠﺔ
ﺴﺠل ﻤﺠﻤﻭﻉ ﻜﺭﻴﺎﺕ ﺍﻟﺩﻡ ﻭ ﻤﺠﻤﻭﻋﺔ ﺏﺎﻟﻤﻘﺎﺭﻨﺔ ﺒ ﻫﺍﻟﻤﺠﻤﻭﻋﺔ  ﻓﻲ  ﻤﻌﻨﻭﻴﺎﹰﻟﺤﺠﻡ ﺍﻟﺩﻡ ﺍﻨﺨﻔﺎﻀﺎﹰ 
 ﻟﻡ ﻴﺴﺠل ﺘﺭﻜﻴﺯ ﺍﻟﺼﻔﺎﺌﺢ ﺍﻟﺩﻤﻭﻴﺔ ﺘﻐﻴﺭﺍﹰ .ﻤﺠﻤﻭﻋﺔ ﺏﺎﻟﻤﻘﺎﺭﻨﺔ ﺒ ﺩ ﻓﻲ ﺍﻟﻤﺠﻤﻭﻋﺔ ﺎﹰﻤﻌﻨﻭﻴ ﺍﻟﺒﻴﻀﺎﺀ ﺘﻐﻴﺭﺍﹰ
ﻭﺠﻭﺩ ﺘﺜﺨﻥ ﻅ ﺤﻭﺍﻷﻨﺴﺠﺔ ﻟ ﻋﻨﺩ ﻓﺤﺹ .ﻤﺠﻤﻭﻋﺔ ﺏﺍﻟﻭ  ه, ﺩ  , ﺠ ﺒﻴﻥ ﻤﺠﻤﻭﻋﺎﺕ ﺍﻟﻤﻌﺎﻟﺠﺔ  ﺎﹰﻌﻨﻭﻴﻤ
 ﺍﺤﺘﻘﺎﻥ ﻨﺠﺩ ﺍﻟﻜﻠﻲﻓﻲ  .ﺏ ﺍﻟﻤﺠﻤﻭﻋﺔﻓﻲ  ﺎﺼﺔﺨ ﻓﻴﻪ ﺒﻠﻭﺭﺍﺕ ﺍﻟﻜﻠﺴﺘﺭﻭلﺘﺭﺴﻴﺏ  ﻤﻊ  ﺍﻷﻭﺭﻁﻲ ﺠﺩﺍﺭﻟ
 ﻓﻲ  .ﺏ ﺍﻟﻤﺠﻤﻭﻋﺔﺒﺭﻭﺘﻴﻨﻴﺔ ﻭﺭﺩﻴﺔ ﺍﻟﻠﻭﻥ ﺩﺍﺨل ﻨﺒﻴﺒﺎﺕ ﺍﻟﻜﻠﻲ ﻓﻲ  ﻭﺠﻭﺩ ﺘﺭﺍﻜﻡ ﻟﻤﺎﺩﺓﻤﻊ  ﺩﻤﻭﻱ
 ﻟﺤﻭﻅﻭ. ﺔﺍﻟﻜﻠﻭﻴ ﺎﺕﺍﻟﺸﺭﻴﻨﺍﻨﺘﺸﺎﺭ ﻟﻠﺨﻼﻴﺎ ﺍﻻﻟﺘﻬﺎﺒﻴﺔ ﺤﻭل ﻭ ﻨﺯﻑ ﺩﻤﻭﻱﺩ ﻭﺠ ﻟﻤﻌﺎﻟﺠﺔﺎﺕ ﺍﻤﺠﻤﻭﻋﺍﻟ
ﻤﻊ ﺍﻨﺘﺸﺎﺭ ﻜﺒﻴﺭ ﻟﻠﺨﻼﻴﺎ  ﻭﺯﻴﺎﺩﺓ ﻓﻲ ﻋﺩﺩ ﺨﻼﻴﺎ ﺍﻟﻐﺩﺩ ﺍﻟﻤﻌﻭﻴﺔ ﻟﻸﻤﻌﺎﺀ ﺍﻟﻅﻬﺎﺭﺓ ﺍﻟﻁﻼﺌﻴﺔﻓﻲ  ﻨﺨﺭ ﻭﺠﻭﺩ
ﺘﻜﻭﻥ ﻓﺭﺍﻏﺎﺕ ﻫﻭﺍﺌﻴﺔ ﻤﻊ ﺯﻭﺍل ﻟﻠﻨﺨﺎﻋﻴﻥ ﻟﻭﺤﻅ ﻓﻲ ﺍﻟﺩﻤﺎﻍ  .ﺎﺕ ﺍﻟﻤﻌﺎﻟﺠﺔﺍﻻﻟﺘﻬﺎﺒﻴﺔ ﻓﻲ ﺍﻟﻤﺠﻤﻭﻋ
  . ﻋﺎﺕ ﺍﻟﻤﻌﺎﻟﺠﺔﻓﻲ ﺍﻟﻤﺠﻤﻭ ﻤﻊ ﺘﺠﻤﻌﺎﺕ ﻟﺨﻼﻴﺎ ﺩﺒﻘﻴﺔ ﺼﻐﻴﺭﺓﺍﻨﺘﺸﺎﺭ ﻟﻠﺨﻼﻴﺎ ﺍﻻﻟﺘﻬﺎﺒﻴﺔ ﻭ ﺩﻤﻭﻱ ﻨﺯﻑﻭ
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Introduction: 
Lipoproteins are a biochemical assembly that contains both proteins 
and lipids. The lipids or their derivatives may be covalently or non-
covalently bound to the proteins. Many enzymes, transporters, structural 
proteins and antigens are lipoproteins. The high density and low density 
lipoproteins enable fats to be carried in the blood stream (Madan et al., 
2003). 
           Lipid and lipoprotein abnormalities are extremely common in the 
general population, and are regarded as a highly modifiable risk factor for 
cardiovascular diseases due to the influence of cholesterol, one of the most 
clinically relevant lipid substances, affecting atherosclerosis.  
Simvastatin belongs to statins, is a cholesterol-lowering drug. It 
reduces cholesterol by inhibiting an enzyme (Hydroxy Methyl Glutaryl - 
CoA reductase (HMG-COA) in the liver, which is necessary for the 
production of cholesterol. In the blood, statins lower total and LDL ("bad") 
cholesterol as well as triglycerides, but increase HDL ("good") cholesterol. 
Raising HDL cholesterol levels and lowering LDL cholesterol may slow and 
even reverse coronary artery disease (Omudhome, 1991). 
         It has been found that Simvastatin exerts side effects, such as 
inflammation of the muscles which lead to rhabdomyolysis. 
Rhabdomyolysis causes the release of muscle protein myoglobin into the 
blood stream, which may cause kidney failure and even death   (Ginelle et 
al., 2007). Simvastatin produced more significant changes on haemostatic 
parameters (Kadikoylu et al., 2003). 
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Recently Simvastatin manufactured by Blue Nile Pharmaceutical 
Factory in Sudan in formula (Hypolip) and used for protection & treatment 
of coronary heart diseases, as well as for obesity. 
Objectives: 
The objectives of the current study are intended to: 
? Provide information on safety and ability of Simvastatin in reducing 
hypercholesterolemia 
? To assess the undesirable effects on renal functions, hematological 







1-1 Plasma Lipids: 
Lipids are organic compounds that are poorly soluble in water but 
miscible in organic solvents. They are a diverse group of compounds that 
have many key biological functions, such as structural components of cell 
membranes, energy storage sources and intermediates in signaling pathways. 
They may be broadly defined as hydrophobic or amphiphilic small 
molecules that originate entirely or in part from two distinct types of 
biochemical subunits or "building blocks": ketoacyl and isoprene groups. 
(Fahy et al., 2005) 
There are four main forms of lipids:  
1. Fatty acids which are straight chain carbon compounds of varying 
lengths. They are either esterified with glycerol to form triglycerides or non-
esterfied fatty acids (NEFA).Plasma (NEFA) provide significant portion of 
energy requirements of the body. They are separated from adipose tissue by 
action of lipase activity, then transported to the liver and muscle mainly 
bound to albumin.(Martin, 2006). 
2. Triglycerides (Trg) transported from the intestine to various tissue as 
lipoproteins.  
3. Phospholipids are complex lipids, containing phosphate in place of 
one fatty acids. They fulfill an-important structural role in cell 
membranes. 
4. Cholesterol which is a steroid alcohol found exclusively in animals 
 4
and present in virtually all cells and body fluids. It is a precursor of 
numerous physiologically important steroids, including bile acids and 
steroid hormones. The rate limiting enzyme of cholesterol synthetic 
path way is 3- hydroxyl-3-methyl glutaryl coenzyme A reeducate, 
(HMG-COA) which is controlled by negative feed back by the 
intracellular concentration of cholesterol.  About two-thirds of the 
plasma cholesterol is esterified with fatty acids to form cholesterol 
esters.(Martin, 2006). 
1-2 Lipoproteins : 
These are spherical, soluble protein complexes which have 
hydrophobic core regions containing cholesterol esters, triglycerides, and 
phospholipids .The protein portion of lipoproteins called Apolipoproteins 
which surround the core and have many types. Apo lipoprotein (B) exists in 
two forms B48, which is formed in the intestine and found in chylomicrons 
and their remnants; and B100 which synthesized in liver and found in Low 
and Very Low Density Lipoprotein. 
Lipoproteins are classified according to their density which inversely 
reflects their size into five groups: 
1-2-1 Chylomicrons:  
These are formed in the intestine and transport triglycerides of dietary 
origin (exogenous), and cholestryl esters. Triglycerides removed from 
chylomicrons in extraheptic tissues by the lipoprotein lipase (LPL) system. 
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1-2-2   Very low Density Lipoprotein: (VLDL): 
They are secreted by the liver and export Triglycerides (Tg) to 
peripheral tissues. The hydrolysis of Triglycerides by Lipoprotein Lipase 
(LPL) yields free fatty acids for storage in adipose tissue and oxidation in 
tissues such as cardiac and skeletal muscles. Depletion of triglycerides 
produces remnants, intermediate low density Lipoprotein IDL, some of 
which are endocytosed directly by liver and the remainder is converted to 
low density lipoprotein by further removal of TG mediated by hepatic lipase 
(Martin, 2006). 
1-2-3 Low Density Lipoprotein: (LDL): 
They are synthezied and secreted from hepatocytes and carried 
cholestryl esters from various tissues to liver .They enter hepatocytes by 
LDL-receptor-mediated endocytosis, a major pathway which catalyzed 
Lipoprotein Lipase (LPL) in hepatocytes and other cells. Cholestryl esters 
from LDL core are hydrolyzed, yielding free cholesterol for the synthesis of 
cell membrane (Martin, 2006).Cells obtain cholesterol by de novo synthesis 
via a pathway involving the formation of mevalonic acid by the enzyme 
HMG- COA reductase.The production of this enzyme and LDL receptors is 
regulated by the concentration of cholesterol in the cell. Liver plays a major 
role in plasma cholesterol level, because 70% of LDL-cholesterol removed 
from plasma by hepatocytes, which are capable to eliminate cholesterol from 




1.2.4 High Density lipoprotein: HDL: 
They transport cholesterol from peripheral tissue to liver. 
Apolipoprteins of HDL, Apo (A) are secreted by the liver and intestine. 
HDL acquires cholesterol from peripheral tissue in a pathway that protects 
the cholesterol homeostasis of cells. In this pathway cholesterol is 
transported from the cell membrane by a transporter protein acquired by a 
small particle termed prebeta -1 HDL, and then esterifies by Lecithin 
Cholesterol Acyl Transferase (LCAT) enzyme, leading to the formation of 
larger HDL,  LDL, and chylomicron remnants with the aid of cholesterol 
ester (Bertram and Katzung, 2004). 
1.2.5  Lipoprotein (a): 
This resembles LDL in lipid composition, but has a higher protein 
content. It is thought to be an independent cardiovascular risk factor (Martin, 
2006). 
1-3 lipids and Lipoproteins disorders: 
Lipids are transported in plasma by lipoproteins. Thus a number of 
metabolic disorders involve elevations in plasma lipoproteins concentrations 
(Hyperlipidemias) occurred. 
The hyperlipidemia denotes increased levels of triglycerides or other 
lipids and lipoproteins fractions (total cholesterol, LDL, VLDL and 
chylomicrons). The important clinical feature of the hyperlipoproteinemia is 
atherosclerosis which leads to coronary heart disease (CHD) which affects 
the arterial wall of blood vessels. The deposition of lipids in these arteries is 
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central to the atherosclerotic process. Elevation of LDL cholesterol (LDL-C) 
is associated particularly with risk of coronary heart disease, however , 
moderately rise in triglycerides or VLDL or remnants  in the presence of low  
level of HDL-cholesterol(HDL-C)  may also be atherogenic. 
Hyperlipidemias are classified based on the pattern of lipoproteins on 
electrophoresis or ultracentrifugation (Frederickson and Lee, 1965). 
Other classification of Hyperlipidemias includes two types of 
hyperlipidemia (Brown, 2001): 
1. Primary hyperlipoproteinamia: is an inherited disorder and have many 
types. Familial hypertriglyceridemia which is associated with 
lipoprotein lipase deficiency (LPL) .The low activity of LPL results in 
decreased removal of triglycerides (TG) from blood stream. Familial 
combined-hyperlipidemia is characterized by increased hepatic 
secretion of apolipoprtoein B-containing VLDL and its conversion to 
LDL.In familial dys-beta lipoproteinemia there is a defect in 
apoliopeprotein E (the major ligand), that allows subsequent 
metabolism of the remnant particles derived from VLDL and 
chylomicrons. Familial hypo-alpha lipoproteinemia in which the 
serum concentration of HDL is low, lead to coronary heart disease 
(CHD) and peripheral vascular disease. Familial hypercholesterolemia 
is characterized by elevation of total cholesterol and LDL-cholesterol 
in plasma. In polygenic hyperlipdemia there is  an increased level of 
total and LDL cholesterol ,but in lesser degree, which results from 
over production of VLDL in the liver due to a combination of high 
dietary fat, obesity and individual susceptibility. It is the most 
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common disorder in adult life with atherosclerosis occruing early but 
with lesser degree. 
2. Secondary hyperlipidemia, results from many factors including liver 
and biliary diseases, Obesity, hypothyroidism, diabetes mellitus, diet, 
excess alcohol, renal disease and glucocorticosteroids drugs (Brown, 
2001). 
1-3-1 Atherosclerosis and Coronary Heart Disease: 
Atherosclerosis is the condition in which an artery wall is thickened as the 
result of a build up of fatty materials such as cholesterol. It is a syndrome 
affecting arterial blood vessels. It is a chronic inflammatory response in the 
walls of arteries, in large part due to the accumulation of macrophage  and 
promoted by low density lipoproteins  without adequate removal of fats and 
cholesterol from the macrophages by functional high density lipoproteins 
(HDL). It is commonly referred to as a hardening or furring of the arteries. It 
is characterized by the formation of multiple plaques within the arteries, this 
lead later on to coronary heart disease (Maton et al., 1993).  
 Coronary heart disease refers to the failure of coronary circulation to 
supply adequate circulation to cardiac muscle and surrounding tissue. It is 
already the most common form of disease affecting the heart and an 
important cause of premature death. (Boon et al., 2006) 
1-4 Management of Hyperlipoproteinemia: 
There are many methods by which hyperlipoproteinemia can be 
managed: 
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1. Lipid lowering diet those who reduced elevated blood cholesterol or 
triglycerides, have decreased risk to coronary heart disease (Erasmus; 
1986). 
2. Lipid lowering plants: World ethnobotanical information reported that 
a     number of herbal medicines from plants and vegetables are used 
for controlling hyperlipidemia and related complications (Dahanukar 
et al., 2000). Sterols (phytosterols) can inhibit intestinal cholesterol 
absorption by up to 50%.Plant sterols dissolved in diacylglycerol oil 
can be effective at a relatively low dose, and can reinforce drugs 
treatment ( Stephen, 2008). 
3. Hypolipidemic drugs or antihyperlipidemic agents.This is a diverse 
group of pharmaceuticals that are used in the treatment of 
hyperlipidemias. They may differ in both their impact on the 
cholesterol profile and adverse effects. Some may lower the "bad 
cholesterol" low density lipoprotein (LDL) more than others, while 
others may preferentially increase high density lipoprotein (HDL), 
"the good cholesterol". Clinically, the choice of an agent will depend 
on the patient's cholesterol profile and cardiovascular risk. (NCEP, 
1986).These agents include Statins, Fibrates, Niacin, Bile acid 
sequestrants, and others which represent a group of hypolipidemic 
drugs. (NCEP, 1986). 
1-4-1 Lipid-lowering diet: 
 Diets rich in cholesterol, saturated fats are principle factors that 
influence plasma LDL levels; where as unsaturated fats and caloric 
restriction is important in management of triglycerides. Sucrose and other 
simple sugars raise plasma VLDL levels in hypertriglyceridemic patients.   
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Some forms of dietary fiber reduce LDL modestly. Alcohol intake can cause 
significant hypertriglyceridemia by increasing hepatic secretion of VLDL. 
Caloric restriction, especially in obese subjects, reduces VLDL and often 
LDL as well. Most patients with elevated LDL can be managed with diet 
restricted in cholesterol and saturated fat but with sufficient calories to 
achieve and maintain ideal body weight. The use of complex carbohydrates 
and fiber is recommended. Exercises which achieve reduction in body 
weight and caloric restriction are especially important for patient with 
elevated VLDL and IDL. The effect of dietary fats on triglyceridemia is 
dependant upon the accumulation of double bond in the fatty acids. Omega-
3 fatty acids are a family of unsaturated fatty acids that have in common a 
final carbon–carbon double bond in the n−3 position; that is, the third bond 
from the methyl end of the fatty acid which  found in fish oils can include 
profound lowering of triglycerides in some patients with endogenous mixed 
lipemia, because it contains low numbers of double bonds (Albert, 2002). 
Patients with primary chylomicronemia and some with mixed lipemia 
must consume diet severely restricted in total fat, but, fat-soluble vitamins 
should be given. Supplementation with naturally occurring antioxidants 
found in fruits and vegatables   (scorbic acid, tocopherols,B-
catchin,selenium ,carotendoids ) and daily supplementation with up to 2 mg 
of folic acids plus Vitamin B3, in doses, (1 to 3 mg/day) may provide 
additional antioxidant defense (Kromhout, 2002). 
1-4-2 Lipid lowering plants:  
Numerous medicinal plants have shown hypolipidemic activity by various 
experimental assay methods. Several of these are available in commercial 
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preparations, either as a single extract or in a combination product (Winston, 
1999). 
  Mukul myrrh tree (Combphara mukul) causes reduction in total 
cholesterol by (14-27%) and 22-30% of triglycerides levels, while HDL-
cholesterol has increased by 20% when 25g of Mukul were given three times 
per day for 12 weeks to a patient with elevated serum cholesterol level 
(Satyavati, 1988). 
Fenugreek (Trigonella fornum) has antihyperlipidemic properties 
when its seed powder was given orally (Patil et al, 1997). The saponine in 
plant fibers increase the loss of bile acids by fecal excretion, which then 
leads to an increased conversion of cholesterol into bile acids by the liver 
(Elson et al, 1998; Hassan, 2001). 
The leaves and fruits of the hawthorn (Crategaus Spp) plant have been 
used widely for cholesterol reduction. Tincture (made from the barriers of 
hawthorn) may be a powerful agent for the removal of LDL-C from the 
blood stream, and reduce the production of cholesterol in the liver of rats fed 
a high cholesterol diet (Schmidt, 1994). 
Black cumin (Nigella sativa) oil was reported to reduce serum total 
cholesterol, triglycerides and LDL-C and significantly increased serum 
HDL- C levels when given orally to rats at a dose of 800 mg /1kg body 
weight for four weeks (El-DakaKhny et al., 2000).  
The thymoquinone , the active ingredient of Nigella Sativa reduces the 
activity of liver cells by increasing conversion of cholesterol into bile acids 
(Amir et al., 2006). 
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The green tea (Camella sinensis) has the ability to lower total 
cholesterol and raise HDL-C levels both in animals and humans. It was 
suggested that the catechins in green tea may block intestinal absorption of 
cholesterol and promote its excretion from the body (Chan et al., 1999; 
Kuan et al., 2004). 
1-4-3 Lipid lowering drugs: 
Drug therapy to lower lipid is used in addition to dietary management 
and correction of other modifiable cardiovascular risk factors (Bennett, 
2003).The use of drug therapy is based on the specific metabolic defect and 
it’s potentiality to cause a atherosclerosis .Diet should be continued for 
achievement of full potential of the drug regimen. Several drugs are used to 
decrease plasma LDL – cholesterol. However, drugs should be avoided in 
pregnant and lactating women and children (Bertram, 2004). 
There are five main classes of drugs used to lower plasma lipids: 
1-4-3-1 Niacin (Nicotinic Acid): 
Niacin (vitamin B3) is converted in the body to the amide, which is 
in- corporated into Niacin amide adenine dinucleotide (NAD). It is excreted 
in the urine unmodified and has several metabolites. Niacin acts as inhibitor 
of VLDL secretion, this in turn decrease the production of LDL. Increased 
clearance of VLDL via Lipoprotein lipase pathway contributes to 
triglycerides reduction, thus the catabolic rate of HDL decreased. Niacin, 
like fibrates, lowers triglycerides by 20-50%. It may also lower LDL by 5-
25% and increase HDL by 15-35%. Niacin may cause hyperglycemia, and 
may   cause liver damage (NCEP, 1985). 
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1-4-3-2   Fibric Acid Derivatives: 
Fibrates are indicated for hypertriglyceridemia. They lower 
triglycerides by 20% to 50%, and increased the level of HDL- cholesterol 
(NCEP, 1985) .Gemifirozil and Penofibrate are the most important 
derivatives. They decrease levels of VLDL and, in some patients LDL as 
well. These drugs primarily act as ligands for the nuclear transcription 
receptor (Peroxisome proliferators – activated receptor alpha (PPR- α). They 
increase lipolysis of lipoprotein, triglycerides via Lipoprotein Lipase (LPL). 
Intracellular lipolysis in adipose tissue is decreased. Levels of LDL decrease 
in part as a result of decreased secretion by the liver (Bertram, 2004). 
Fibrates had a risk of severe muscle damage myopathy & 
rhabdomyolysis (NCEP, 1986). 
1-4-3-3 Bile Acid Sequestrants (Resins): 
These are polymeric cationic exchange resins that are insoluble in 
water. They include clolestrylamine and colesevelam. They are particularly 
effective for lowering LDL-cholesterol by sequestering the cholesterol-
containing bile acids released into the intestinal lumen and preventing their 
re absorption from the intestine. Excretion of  bile is increased  to ten-fold 
when resins are given, resulting in enhanced conversion of cholesterol to 
bile acids in liver via  hydroxylation of  LDL  receptors (Bertram, 2004).It 
decreases LDL by 15-30% and raises HDL by 3-5%. It has little effect on 
triglycerides. They may cause gastrointestinal problems, and may also 
reduce the absorption of other drugs and vitamins from the gut. ((NCEP, 
1985) 
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1-4-3-4 Inhibitors of intestinal Sterol Absorption: 
Ezetimibe is the first member of this group of drugs that inhibit 
intestinal absorption of phytosterols and cholesterol. Its clinical effect is to 
reduce LDL levels. They act as selective inhibitors of intestinal absorption 
of cholesterol. It is effective even in the absence of dietary cholesterol, 
because it inhibits re absorption of cholesterol excreted in the bile. (Bertram, 
2004). 
1-4-3-5 Competitive inhibitors of HMG-COA reductase (Statins):  
Akira Endo et al (1976) stated that certain microorganisms may 
produce inhibitors of the enzyme (HMG-COA reductase) to defend 
themselves against other organisms. Mevalonate is a precursor of many 
substances required by organisms for the maintenance of their cell wall 
(ergosterol) or cytoskeleton (isoprenoids) (Endo, 1992).   
Statins are a group of medications which are widely prescribed for 
treating atherosclerosis (The Allhat Officers et al, 2002). 
A group of drugs belong to statins include lovastatin, atorvastatin, 
fluvastatin, pravastatin, simvastatin, and rosuvastatin (Bertram, 2004).  
Statins are particularly well-suited for lowering LDL- cholesterol with 
the strongest links to cardiovascular diseases. Statins have been found to 
lower LDL-C by 18% to 55%, depending on the type used (NCEP, 1986). 
They also decreased oxidative stress and vascular inflammation with 
increased stability of atherosclerotic lesions (Bertram, 2004). 
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1-4-3-5-1 Chemistry and pharmacycokinetics: 
Lovastatin and simvastatin are inactive lactone pro-drugs, which are 
hydrolyzed in gastrointestinal tract to the active B-hydroxyl derivatives, 
where as, pravastatin has an open active lacatone ring. Atorvastatin, 
fluvastatin and rosuvastatin are active fluorine-containing congeners. The 
absorption of the ingested doses of these drugs range from 40% to 75% with 
the exception of fluvastatin, which is completely absorbed. All of them 
extracted by liver and most of the absorbed dose is excreted in the bile, 
about 5-20% is excreted in the urine. Plasma half-life of these drugs range 
from I to 3 hours except for a torvastatin, which has a half – life of 14 hours, 
and rosuvastatin, 19 hour (Bertram, 2004). 
1-4-3-5-2  Metabolism: 
The catabolism of lovastatin, simvastatin, and atorvastatin proceed 
chiefly through cytochrome P450 3A4, where as, that of fluvastatin and 
rouvastatin is mediated by cytochorme P2 CP .Pravastatin is catabolised 
through other pathways, including sulfations (Bertram, 2004). 
1-4-3-5-3 Mechanism of action: Cholesterol-lowering pathway: 
Statins act by inhibiting the enzyme HMG-CoA reductase, the enzyme 
controlling the first step of cholesterol synthesis, in the liver. Because statins 
are similar to HMG-CoA on a molecular level they take the place of HMG-
CoA in the enzyme and reduce the rate by which it is able to produce 
mevalonate, the next molecule in the cascade that eventually produces 
cholesterol, (Figure 1).Inside the liver cell, other enzymes of the protease 
class sense the decreased level of cholesterol produced. In response, they 
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cleave a protein called "membrane-bound sterol regulatory element binding 
protein", which then responds by migrating to the nucleus to increase 
production of various other proteins and enzymes, including the LDL 
receptor. The LDL receptor then relocates to the cell membrane of the liver 
cell, and binds to pass low density lipoprotein and very low density 
lipoprotein particles (both containing cholesterol in the undesired form). 
LDL and VLDL enter the liver and is digested (Ma PT et al., 1986). 
1-4-3-5-4 Non-cholesterol related actions of statins: 
Statins exhibit action beyond lipid-lowering activity in the prevention 
of atherosclerosis. Statins prevent cardiovascular diseases via four proposed 
mechanisms, improve endothelial function, modulate inflammatory 
responses, maintain plaque stability, and prevent thrombus formation 
(Furberg,  1999) 
1-4-3-5-5  Toxicity: 
  Statins therapy rarely, have marked elevations in kinase activity, but 
often accompanied by generalized pain or weakness in skeletal muscles. If 
the drug is not discontinued, rhabdomyolysis may cause myoglobinuria, that 
lead to renal shutdown. Rarely, hypersensitivity syndromes that include a 





Figure (1) Cholesterol-lowering pathway: 
Source: en: Image: HMG-CoA_reductase_pathway.png 
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1-5 Simvastatin (Hypolip): 
Is a hypolipidemic drug belonging to statins. It is used to control 
hypercholesterolemia and to prevent cardiovascular diseases. Simvastatin is 
a synthetic derivate of a fermentation product of Aspergillus terreus. Olivia 
et al. (1998) synthetically derived it, and pointed that it is a potent HMG-
COA reductase inhibitor. 
1-5-1    Chemical structure: 
Simvastatin is a butanoic acid, 2.2-dimethyl- 1,2,3,7,8,8 a hexahydro-
3,7- dimethyl-8,1-2 tetrahydro-4-hydroxy-6- oxo-2H-pyran-2-yl)-ethyl ester 
(Fig 2). 
The empirical formula of simvastatin is C25 H38 O5 and its molecular 
weight is 418.57g/mol. 
It is a white, non hygroscopic, crystalline powder that is practically 
insoluble in water, and freely soluble in chloroform, methanol, and ethanol. 
It is used in a dose of 5 up to 80 mg, administrated orally with their inactive 
ingredients cellulose, hydroxyl propyl cellulose, hydroxyl methylcellulose, 
iron oxides and lactose.  
1-5-2 Clinical Pharmacology: 
Simvastatin is a specific inhibitor of HMG-COA reductase, the 
enzyme that catalyzes the conversion of HMG-COA to mevalonate (an early 
step in the biosynthetic pathway for cholesterol). Simvastatin has been 
shown to reduce both normal and elevated LDL cholesterol (LDL-C) 
concentration. The mechanism of the LDL lowering effect of simvastatin 
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may involve both reduction of VLDL cholesterol concentration, and 
induction of the LDL receptor, leading to reduction or increased catabolism 
of LDL-C and Apo B concentration falls substantially during treatment with 
simvastatin (Lilja et al., 1998). 
Zhou et al., (2006) stated that, simvastatin significantly reduced the 
risk of mortality by 30% and the risk of coronary heart (CHD) by 42%.They 

































Simvastatin is a lactone that is readily hydrolyzed to the 
corresponding B-hydroxyl acid, a potent inhibitor of HMG-COA reductase. 
Inhibition of this enzyme is the basis for an assay in pharmacokinetic studies 
of the beta hydroxyl acid metabolites. In animal   studies, after oral dosing, 
simvastatin achieved substantially higher concentrations in the liver than 
other tissue. Simvastatin undergoes extensive extraction in the liver, its 
primary site of action, by the enzyme cytochrome P3 A4 (CY p3 A4) with 
subsequent extraction of drug equivalents in the bile. Both simvastatin and 
its B-hydroxyl acid metabolite are highly bound (95%) to plasma protein. 
The bioavailability is 5% and the half life is 3 hours (Manson et al., 1996). 
 The principal route of elimination is the renal system (urine at 13%) 
and biliary system (feces at 60%) (Manson et al., 1996). 
1-5-4 Indications: 
Simvastatin is indicated in patients with coronary heart disease (CHD) 
or at high risk of CHD to reduce the mortality, the recommended usual 
starting dose is 20-40 mg once a day in the evening. For patients with 
hypercholesterolemia to reduce elevated total cholesterol, LDL-cholesterol, 
ApoB and Triglycerides and to increase HDL-C, the recommended dose is 
40 mg/Kg /day or 80 mg/Kg/day in three divided doses. The minimum goal 
of treatment in adolescent patients is to achieve a mean LDL-C < 130 mg, 
the recommended usual starting dose is 10 mg once a day in the evening. 
When using simvastatin therapy, secondary causes of hypercholesterolmia   
like hypothyroidism, diabetes, liver disease should be excluded, and lipid 
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profile should be performed Total- cholesterol, HDL-cholesterol and 
Triglycerides at intervals of 4 weeks and dosage adjusted according to the 
patient’s response to therapy (NCEP, 1992). 
1-5-5 Contraindications: 
Simvastatin is contraindicated during pregnancy and in nursing 
mothers, because of the ability of HMG. COA reductase inhibitors to 
decrease the synthesis of cholesterol biosynthetic pathway which are 
essential components for fetal development.  Also it is contraindicated in 
patients with active liver disease or unexplained persistent elevations of 
serum transmarine (Omudhome, 1991). 
1-5-6 Warnings: 
Simvastatin in high doses occasionally causes myopathy which some 
times takes the form of rhabdomyolysis with or without renal failure. When 
drug treatment continued for a long period,persistent increases in serum 
transaminases have occurred in 1% of patients who received  simvastatin 
therapy(Omudhome, 1991). 
1-5-7 Drug Interactions: 
The risk of myopathy is increased when other lipid-lowering drugs are  
used concomitant with simvastatin (Graham et al., 2004). 
Grapefruit juice may increase the amount of the drug in bloodstream, 
because grapefruit contains the flavonoid naringenin, which inhibits the 
enzyme cytochrome p450 3, this in turn slows metabolization of simvastatin 
.Therefore patients taking simvastatin should restrict their intake of 
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grapefruit –containing products (Bailey and Dresser, 2004). 
1-5-8 Adverse Reactions 
Adverse reactions have usually been mild and transient, but in the 
controlled clinical studies 1.4% of patients were discontinued due to adverse 
events attributable to simvastatin (Taves, 1974). 
In Safety and tolerability profiles study of simvastatin, involving 4444 
patients treated with 20-40 mg/day of simvastatin, the results are abdominal 
pain, diarrhea, nausea   , myalasia, and skin rash. In protection study, 
involving 20.530 patients treated with simvastatin 40 mg/day the incidence 
of myopathy was < 0.1. Other clinical studies reported effects with statins 
therapy, in laboratory tests, marked persistent increases of serum 
transaminases have been noted and about 5% of patients had elevations of 
creatine kinase (Silva et al., 2007). 
  Simvastatin   produced more significant changes on haemostatic 
parameters and had increased effects, when doses were increased from 10 to 








Materials and Methods 
2.1 Materials  
2.1.1 Experimental animals: 
Twenty five Wistar albino rats of both sex, weighing (100-220) g 
were used in this study .They were obtained from Faculty of Pharmacy, 
University of Khartoum. They were housed under standard conditions, under 
the care of Medical and Aromatic Plants Institute (MAPI).They had free 
access to water and normal diet. They were kept for two weeks as an 
adaptation period. 
2.1.2 The diet:  
The basal diet which provided the nutritional requirements to rats was 
composed of the following constituents (per Kg): 
Wheat flour   660g 
Dry meat   147g   
Plant oil   120g 
Sodium chloride       3g  
2.1.3 Simvatatin (Hypolip): 
The powder form of the drug was supplemented by Blue Nile 
Pharmaceutical Factory. The different concentrations of the drug were 
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prepared by dilution of the powder .The stock solution was prepared by 
dissolving 100mg simvastatin in 100ml distil water, the solutions were 
stored in a refrigerator to be used at the time of administration. The 
concentration of simvastatin was 1mg/ml, and then the doses were calculated 
according to rat’s weight. 
2.1.4 Cholesterol:  
The powder form of 1%cholesterol was supplemented from Lab Line 
Company and was added to the rat’s basal diet to induce 
hypercholesterolemia according to the method of (Birkner et al., 2009). 
2.1.5 Experimental design: 
After adaptation period, the rats were divided randomly into 5 groups, 
five in each.  Group (A) fed normal diet only and was left as control. Group 
B was fed 1%cholesterol –containing diet for2 weeks and stopped, and then 
they were continued with normal diet. Groups C, D and E were fed 
1%cholesterol –containing diet for 2 weeks, and then were orally 
administrated Simvastatin, using nasogastric tube, once per day at 
concentrations of 10, 40, 80 mg/kg Body weight (Bwt), respectively for 
4weeks. 
2.2 Methods: 
2.2.1  Collection and preparation of Blood samples: 
  Blood samples were taken every 2 weeks to investigate plasma lipid 
profile, renal functions and hematology. The blood was obtained from the 
orbital plexus vein by the mean of heparinized capillary tube , 2 ml of blood 
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was collected in heparinized containers, then centrifuged at 5000 rpm for 15 
minutes and the supernatant plasma   was immediately separated and frozen 
at -20 ْC until analyzed., according to method of (Scalm, 1965).  
2.2.2 Roche Diagnostic / Hitachi 902 analyzer: 
It is an automatic analyzer which is used to report test results on 
various body fluids. It is computerized and performs potentiometric and 
photometric assays. It consists of processing unit, photometric measuring 
system and luminance crystal display (LCD) touch screen, with standard 
printer to print test results. It is performs 200 photometric tests per hour, and 
refrigerated storage for 40 reagents containers, as well as it has end point, 
kinetic and enzymatic reductions. 
Principle:  
There are two fundamental types of photometric assays on this instrument: 
• End point: The measurements are taken by a photometer at 
specific measure points. Measurements are taken after the reactions have 
been completed). 
• Rate assays: The measurements are taken as the reactions 
proceed. Measurements are taken before the reaction stopped, the intensity 





2.2.3 Ion Selective Electrode (ISE): 
The electrode method is mainly used for measurement of electrolytes 
concentration such as sodium ion, potassium ion, and chlorine ion. This 
technique tests assemble assays on a single sample at the same time. 
An ion selective electrode of flow through type is used for 
electrochemical measurement of ion species contained in a biological fluid 
by the electrode method. In the electrode method, the reaction of an ion and 
a sensing substance contained in an ion-sensing membrane is 
electrochemically detected. Pluralities of holes are made on a part of the wall 
of a path for letting the biological fluid flow there through. An ion-sensing 
membrane is formed in the plurality of holes such that each membrane 
includes a different sensitive ion from the other and the inner surface of the 
path is kept smooth.  
2.2.4 Sysmex-KX-21N: 
The KX-21 is a fully automated hematology analyzer, easily fitting 
into any laboratory.  It is an automatic multiparameter blood cell counter for 
in vitro diagnostic use in clinical laboratories .This machine process 
approximately 60 samples per hour and displays on the LCD screen, the 
particle distribution curves of WBCs, RBCs, PCV%, Hb concentration and 
platelets along with data of other parameters as the analysis results.  
2.2.5 Biochemical methods: 
 All serum investigations were measured by using Hitachi 902 in 
Research and Laboratories unit, Khartoum Teaching Hospital. 
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2.2.5.1 Measurement of serum total cholesterol (TC): 
Reagents 
Reagent composition:     Final concentrations  
Good’s Buffer PH6.7    80 mmol/L 
Phenol       5mmol/L 
4. Aminoantipyrine    0.3mmol/L 
Cholesterol esterase (CHE)   ≥ 200 V/L 
Cholesterol oxidase (CHO)   ≥ 50 V/L 
Peroxidase (POD)               ≥  3 k/L 
Principle:  
Cholesterol ester + H2O    CHE     cholesterol + fatty acids 
Cholesterol + O2    CHO      cholesterol -3-one + H2O2 
2H2O2 + phenol +4Aminoantipyrine   POD   Quinoneimine   + 4H2O 
                                                                           (Pink color) 
The intensity of the pink/red color of the Quinoneimine is proportional to the 
cholesterol concentration in the sample (Roeschlau et al., 1974).The test has 
been developed to determine cholesterol concentrations with in a measuring 
range from 3-800 mg/dL on Hitachi. 
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 Procedure: 
500 µL of plasma samples were put in Hitachi sample cups. The 
sample cups were entered in a specific place on Hitachi 902 and then the 
parameters to be measured were selected from the touch screen and 
registered automatically. Thereafter, the machine was put on and the results 
were printed in ten minutes.Hitachi 902 machine adds 500µL from sample 
and reagent, and the reaction proceeds automatically. 
Calculations:  
The analyzer automatically calculates the analyte concentration of 
each sample and the results appear directly on the LCD touch screen at the 
end of the reactions between the samples and reagent. 
Cholesterol concentration (mg/dl) =        O.D of the test             × standard 
concentration 
                                                               O.D of the standard    
O.D: optical density 
2.2.5.2 Measurement of serum low Density Lipoprotein (LDL)  
Reagent Composition: 
Reagent (1)           final concentration 
Good’s Buffer PH6.8      25 mmol/L 
Cholesterol Esterase (CHE)     5000 U/L 
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Cholesterol Oxidase (CHO)     5000 U/L 
N-(2-Hydroxy-3-sulfopropyl)-3,5dimethoxyaniline (HDAOS) 
                                                                                   0.64 mmol/L 
Castalase                                                                    1000 KU/L     
Reagent (2)        
Good’s Buffer PH 7.0           25 mmol/L 
4Aminoantipyine            3-5 mmol/L 
Peroxidase (POD)            20 KU/L 
Sodium azide 
Principle: 
In this method, non-LDL lipoproteins are enzymatically processed, 
while LDL is selectively protected in the first incubation step with reagent 
(I). In the second step, LDL is released and selectively determined 
(Bachorik, 1997). 
LDL-c + protecting reagent (reagent 1)                     protected LDL-c 
HDL-c, VLDL, chylomicrons    CHE, CHO      cholestenone H2O2 
HDL-c   CHE, CHO    cholestenone + H2O2 
H2O2 + 4.Aminoantipyrine + H-DAODS   POD       (blue colored complex) 
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The test has been developed to determine LDL concentrations within a 
measuring range from 1-400 mg/dl. 
Procedure: It is similar to that used in cholesterol measurement 
Calculation: It is similar to that used in cholesterol measurement 
2.2.5.3 Measurement of Serum High Density Lipoprotein (HDL): 
Reagent composition  
Reagent (1): 







Good’s buffer (PH 7) 
Sodium azide  
4Aminoanti pyrine.            Peroxidase. 
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Principle: There are two steps of a direct method: 
1. Elimination of chylomicron, VLDL and LDL-C by the enzyme 
cholesterol esterase, cholesterol oxidase and subsequently cholesterol 
catalase. 
Cholesterol  ester      Esterase       cholesterol + fatty acid.     
Cholesterol + O2   cholesterol oxidase    cholestenone +  H2O2  
2 H2O2          catalase        2 H2O + O2   
Specific measurement of HDL–c, after the release of HDL–c by detergent in 
reagent (2), the intensity of quinoneimine dye produced is directly 
proportional to the cholesterol concentration. 
2H2O2 + 4aminoantipyrine + N-(2-hydroxy-3-sulfopropyl)- 
3,5-dimethoxyaniline   peroxidase    Quinoneimine (pink color) + 4H2 O 
The assay is linear up to 600 mg/dl. 
Procedure: It is similar to that used in cholesterol measurement 
Calculation: It is similar to that used in cholesterol measurement 
2.2.5.4 Measurement of Triglycerides (Tg): 
Reagent composition  
Components      final concentrations  
Good’s Buffer PH 7.2     50 mmol/L 
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4 chlorophenol       4 mmol/L 
Mg+2       15 mmol/L 
ATP: Adenosine Triphosphate             2 mmol/L 
Glycerol kinase (GK)     ≥ 0.4 KU/L 
Peroxidase (POD)      ≥ 2 KU/L 
Lipoprotein lipase (LPL)     ≥ 2 KU/L 
4 Amino antipyrine      0.5 mmol/L 
Glycerol -3- phosphate – oxidase (GPO)   ≥ 0.5 KU/L 
Principle: 
Determination of triglycerides is done according to enzymatic 
splitting with lipoprotein lipase. Indicator is quinoneimine which is 
generated from 4-aminoantipyrine and 4-chlorophenol by hydrogen peroxide 
under the catalytic reaction of peroxidase (Cole et al., 1997). 
Triglycerides     LPL       glycerol + fatty acid  
Glycerol +    ATP        GK      Glycerol -3- phosphate + ADP 
Glycerol-3-phosphate+ O2    GPO       Dihydroxyaceton phosphate + H2O2 
2H2O2+ aminoantiphrine + 4chlorophenol     POD     Quinoneimine + HCL 
+ 4 H2O 
The assay is linear up to 1300 mg/dL (on Hitachi). 
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 Procedure: It is similar to that used in cholesterol measurement 
Calculation: It is similar to that used in cholesterol measurement 
2.2.5.5 Measurement of Blood Urea: 
Reagents composition: 
Reagent 1   
Components              final concentrations  
Tris Buffer, PH7.8     120 mmoL/L 
2-Oxoglutrate                7 mmoL/L 
ADP: Adenosine Diphosphate    0.6 mmol/L                         
 Urease         ≥ 6 KU/L 
Glutamate dehydrogenase               ≥ 1 KU/L 
Reagent 2 
 NADH: reduced NAD: Nicontinamide Adenosine Dinacleotide                          
0.25 mmoL/L 
Principle:  
Following an initial phase, the rate of the reaction is constant for 60 
seconds. Decrease in absorbance, resulting from the GLHD reaction is 
proportional to the concentration of Urea in the sample (Thomas, 1998).The 
 35
test has been developed to determine urea concentrations within a 
measurement range from 2.600 mg/dL in serum or plasma on Hitachi. 
Urea + 2 H2O  Urase       2 NH+2 + 2 HCO-3 
NH+4 + 2- oxoglutrate      GLDH      L- Glutamate + NAD+ + H2O 
Procedure:  
Hitachi 902 machine automatically adds 500µL from samples, reagent 
1 and reagent 2 and the reactions proceed immediately until the contents 
finished. 
Calculation:  
The analyzer automatically calculate the analyze concentration of 
each sample and the results appear directly on the LCD touch screen at the 
end of the reactions between the samples and reagent. 
2.2.5.6 Measurement of Serum Creatinine: 
Reagents composition  
Reagent 1     Final concentrations  
Sodium Hydroxide    0.16 mmoL/L 
Reagent 2: 
Picric acid      4.0 mmoL/L 
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Principle: The assay is based on the reaction of creatinine in the sample 
with an alkaline solution of sodium picrate to form a red complex. The red 
color is proportional to the concentration of creatinine in the sample 
(Newman and Price, 1999). The assay is linear up to 15g/dL 
Procedure: It is similar to that used in urea measurement 
Calculation: It is similar to that used in urea measurement 
2.2.5.7 Measurement of Serum Sodium & Potassium: 
Reagent: SnapPak is intended for use only in the Electrolyte Analyzer. 
Contents:                      Standard A                   Standard B             Standard C 
                                       mmol/L                        mmol/L                     mmol/L                           
Active Ingredients 
Sodium                       150.0                                100.0                             150.0  
Potassium                  5.0                                      1.8                                    5.0  
Chloride                   115.0                                   72.0                              115.0  
Calcium                   0.9                                      1.5                                     0.9  
Lithium                    0.3                                    0.3                                       1.4  
Principle: 
In the electrode method, the reaction of an ion and a sensing substance 
contained in an ion-sensing membrane is electrochemically detected.  
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Procedure: 
Pluralities of holes are made on a part of the wall of a path for letting 
the biological fluid flow there through. An ion-sensing membrane is formed 
in the plurality of holes such that each membrane includes a different 
sensitive ion from the other and the inner surface of the path is kept smooth.  
2.3 Hematological methods: 
 Blood samples were collected by slaughtering animals and 
immediately placed into dry -cleaned tubes containing Ethylene Diamine 
Tetra acetic Acid (EDTA) as an anticoagulant. The hematological analysis 
was done by the mean of Sysmex -KX-21 N. 
2.4 Histopathological methods: 
 After rats were slaughtered, specimens from kidney, aorta, brain and 
intestine were immediately removed and fixed in 10% neutral Formalin 
(sodium hydrogen 6.5 gm/L and sodium dehydrogenate 4.0 gm/L0. Then 
they were embedded in paraffin wax, and sectioned at 5µm and stained by 
Hemotoxyline and Eosin (H&E) using (Druray and Wallington method 
(1980).  
2.5 Statistical analysis: 
 The obtained data were subjected to one-way analysis of variance 
(ANOVA) by Completely Randomized Design (CRD), and the data were 





3.1 Body weight: 
The mean changes in body weight in induced hypercholesterolemic 
rats were presented in table (1).  
There were no   significant changes in body weight between groups 
(B, C, D, and E) fed 1% cholesterol diet and the control (A) which fed 
normal diet only after 2weeks. 
However, there was a significant increase (P< 0.05) in body weight in 
groups (B, C, D, and E) compared to the control (A) after 6weeks.  
 3.2 Induction of hypercholesterolemia: 
The effects of feeding 1% cholesterol-containing diet for 2weeks on 
plasma Total cholesterol and LDL-c in albino rats is presented in table (2) 
and figure (8). 
The plasma levels of Total cholesterol (T.C) concentrations showed a 
highly significant increase (P < 0.01) in groups (B, C, D and E) fed 
1%cholesterol diet compared to the control (A) after two weeks. 
The plasma levels of Low Density Lipoprotein- cholesterol (LDL-C) 
showed a significant increase (P< 0.05) in groups (B, C, D, and E) fed 
1%cholesterol diet compared to the control (A) after 2weeks. 
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There was a significant increase (P < 0.01) in plasma LDL-c in group 
(D) (132.97±6.7 mg\dl) compared to group (B) (91.60±4.8 mg\dl).However, 
there were no significant changes in plasma LDL-c in groups (C, E) 
compared to group  (B). 
 3.3 Plasma lipid profiles: 
3.3.1 Total cholesterol (T.C): 
The effect of oral administration of simvastatin on T.C in an induced 
hypercholesterolemic rats is presented in (table 3), (fig 9, 10) 
There was a significant decrease (P<0.05) in plasma Total Cholesterol 
(T.C) in group(C) received 10mg/kg Bwt of Simvastatin (68.75±4.1mg\dl) 
compared to the control (B) (79.75±4.5mg\dl) after two weeks of the 
administration of Simvastatin .But, there was no significant decrease in 
groups (D, E) that received 40, 80 mg/kg, respectively, compared to the 
control group (B) after 2weeks.  
There was a highly significant decrease (P<0.01) on plasma T-
cholesterol in group (E) that received 80mg/kg of Simvastatin (55.67±3.7 
mg\dl) compared to the control group (B) (107.7±5.2mg\dl) after 4weeks of 
the administration of Simvastatin. However, the plasma T.C showed no 
significant decrease in group(C, D) compared to the control group (B) after 
4weeks of the experiment. 
3.3.2 Low Density Lipoprotein-cholesterol (LDL-c):  
The mean changes on plasma LDL-c in an induced hypercholesterolemic rat 
treated with simvastatin is presented in (table 3), (fig 9, 10). 
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There was a significant decrease in plasma LDL-c in groups (C, D and 
E) that received 10, 40,80mg/kg of simvastatin and (26.95±2.6, 22.10±2.4, 
25.43±3.2mg\dl), respectively, compared to the control group (B) 
(41.47±3.2mg\dl) after 2weeks of administrating of simvastatin.On the other 
hand, there was a significant decrease (P<0.05) on LDL-c in groups (D, E) 
that received 40, 80 mg /kg simvastatin (31.00±2.9, 33.80±3.4)mg\dl, 
respectively, compared to the control group (B) (46.47±3.4mg\dl) after 
4weeks of the experiment. However, there were no significant differences in 
T-cholesterol in groups (C) that received 10mg/kg of simvastatin compared 
to group (B). 
3.3.3 High density lipoproteins: 
The mean changes on plasma LDL-c in an induced 
hypercholesterolemic rats treated with simvastatin is presented in table (4), 
figure (9, 10). 
There was a significant increase (P<0.05) in levels of plasma HDL-c 
in groups (D, E) that received 40, 80 mg /kg Bwt simvastatin   (55.53±3.7, 
46.93±3.4mg\dl) respectively, compared to group (B) fed 1% cholesterol 
diet (30.75±2.8mg\dl) after2 weeks of the experiment. . However, there was 
no significant difference in HDL-cholesterol in group (C) that received 10 
mg/kg of simvastatin compared to group (B).  
3.3.4 Triglycerides: 
The effect of oral administration of Simvastatin on plasma Triglycerides in 
an induced hypercholesterolemic rats is presented in table (4), figures (9, 
10). 
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There was a significant decrease (P<0.05) in plasma Triglycerides 
after 2weeks, in group (E) that received 80 mg/kg Bwt of simvastatin 
(82.25±4.5mg\dl) compared to control (B) (128.75±5.7mg\dl). 
However, the plasma level of Triglycerides showed no significant 
differences in groups (C, E) that received 10, 40, mg/kg Bwt, respectively,  
compared to the  control group (B) (128.75±5.7mg\dl) after 2weeks of 
simvastatin administration. 
There was a significant decrease (P<0.05) in plasma triglycerides in 
groups (D, E) by (69.75±4.2, 60.33 ±4.5) mg\dl compared to the control (B) 
(84.00±4.6mg\dl) after 4weeks of Simvastatin administration in Rats. 
However, there were no significant changes in Triglycerides level in group 
(C) (94.33±5.6mg\dl) compared to the control group (B) (84.00±4.6mg\dl) 
after 4weeks of simvastatin administration.  
3.4 Renal profile: 
3.4.1 Blood urea & Creatinine: 
The mean changes on Blood Urea in an induced hypercholesterolemic rats 
treated with Simvastatin is presented in table (5), figure (11). 
There was no significant changes in plasma levels of urea between 
treated groups (C, D, E) that  received 10, 40, 80 mg\kg Bwt, respectively 
and the control group (B) after 2 weeks of administration of 
Simvastatin.However, the levels of blood urea reported a significant 
decrease (P>0.05) in groups (C, D and E )  (46.00±3.9 , 42.25±3.3 , 
31.00±2.8mg/dL) respectively,  compared to the  control group (B) 
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(58.50±3.8mg/dL) after 4weeks of the administration of Simvastatin in an 
induced hypercholesterolemic rats . 
Serum Creatinine levels showed no significant differences in treated 
groups (C, D and E) of rats compared to the control group (B) through out 
the experimental period. 
3.4.2 Sodium and Potassium 
The effect of Simvastatin on serum Potassium and sodium is 
presented in table (5) and figure (12). 
There was no significant changes in the levels of serum potassium and 
sodium between treated groups (C, D, E) that received (10, 40, 80mg\kg 
Bwt), respectively and the control group (B) after 4weeks of the 
administration of Simvastatin in an induced hypercholesterolemic rats. 
3.5 Hematological findings:  
3.5.1 Red Blood Cell Counts (RBCs): 
The effect of oral administration of simvastatin on hematological 
parameters is presented in table (5). 
There were no significant differences in Red Blood Cell Count 
between treated groups(C, D, and E) and the control group (B) after 4weeks 
of administration of Simvastatin. 
3.5.2White Blood Cell Counts (WBCs):  
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There was a significant decrease (P<0.05) in WBCs in group(D) that 
received 40mg\kg Simvastatin (8.100±1.4)×10mm³) compared to the control 
group (B) (16.733±2.4)10mm³) after 4weeks of administration of 
Simvastatin in hypercholesterolemic rats. However, the WBCs showed no 
significant changes in groups (C, E) that received (10,40mg\kg Bwt, 
respectively, compared to the control group (B). 
3.5.3 Hemoglobin concentrations (Hb): 
There was a significant decrease (P<0.05) in (Hb) concentration in 
group (E) that received 80mg\kg Bwt (7.850±1.4 ×10g/dL) compared to the 
control group (B) (11.450±1.7g/dL), however, there were no significant 
differences in hemoglobin concentration in groups (C ,D ) compared to the 
control group (B). 
3.5.4 Packed Cell Volume (PCV %): 
There was a significant decrease (P<0.05) in PCV values in group (E) 
by (27.10±2.6) compared to the control group (B) (38.48±3.1) after 4weeks. 
However, there were no significant changes in groups (C, D) compared to 
the control group (B) after 4weeks of experiment. 
3.5.5 Platelets: 
There were no significant changes on platelets concentrations between 
treated groups of rats (C, D, E) that received (10, 40, 80) mg\kg Bwt, 
respectively, and the control group (B) in an induced hypercholesterolemic 
rats after 4weeks of experiment. 
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3.6 Histopathological findings: 
  In group (B) which fed 1%cholesterol containing diet, the aortal wall 
was thickened with precipitation of cholesterol clefts (Fig 3). The kidney 
showed congestion and infiltration of inflammatory cells (Fig 4). 
  In group(C) which received 10mg/kg Bwt of Simvastatin, the 
intestine showed, necrosis of epithelial cells, increase number of goblet cells, 
infiltration of inflammatory cells (Fig 5). 
In group (D), the kidney showed hemorrhage, segmented golmeruli, 
infiltration of inflammatory cells surrounding a blood arteriole (Fig 6).  
In group (E) which received 80mg/kg Bwt of Simvastatin, the Brain 
showed, congestion, vaculation, demyelation of neurons, and infiltration of 










Table (1): The effect of feeding 1% Cholesterol diet on rat’s body weights 




Values are presented as Means ± SE (standard errors)   
   Significant:    (P<0.05)*      
Groups: 
(A): fed normal diet: control  




Body weight in gm 
Initial weight 6 week 
A 150 ±5.48 164.5±6.41 
B 148.75 ±5.45 172.5  ±   6.57* 
C 143.75 ±5.36 171.25 ±  6.54  * 
D 145   ±5.39 172.5   ±   6.57 * 
E 143.75±5.36 172.5   ±   6.57* 
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Table (2): Mean changes in plasma Total cholesterol and LDL-cholesterol in 







Values are presented as Means ± SE (standard errors)  
Highly significant   ** (P<0.01)    
Groups: 
(A): fed normal diet only. 




Groups T.C LDL-c 
A  52.75 ± 3.6 12.07±1.7 
B  155.33 ± 7.2** 91.60±4.8** 
C  122.50 ± 5.5** 69.50±4.2** 
D  193.33 ±8.1** 132.97±6.7** 
E  128.00 ± 5.7** 71.58±4.2** 
Period (weeks) Groups T.C LDL-c 
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Table (3): Mean changes in plasma T-cholesterol & LDL-cholesterol in an 
induced hypercholesterolemic rats treated with Simvastatin: 
Values are presented as Means ± SE (standard errors)  
 Significance             *    (P<0.05)   
Highly significance **   (P<0.01) 
Groups: 
(A): control (fed normal diet only). 
 (B): fed cholesterol-containing diet 1% only. 
(C): fed cholesterol-containing diet 1% &received 10 mg/kg simvastatin. 
(D): fed cholesterol-containing diet 1%& received 40 mg/kg simvastatin. 
(E): fed cholesterol-containing diet 1%& received 80 mg/kg simvastatin 
2 B 79.75  ±4.5 41.47±3.2 
 C 68.75 ±4.1 26.95±2.6* 
 D 84.00 ± 4.6 22.10±2.4* 
 E 77.00 ± 4.4 25.43±2.5* 
4 B 107.7  ±5.2 46.47±3.4 
 C 86.33 ± 5.4* 39.47±3.6 
 D 82.00 ± 4.5* 31.00±2.9* 
 E 55.67 ± 3.7** 33.80±3.4* 
Period(weeks) Groups(Doses) HDL     Triglycerides
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Table (4) Mean changes in plasma HDL &Triglycerides in an induced 
hypercholesterolemic rats treated with Simvastatin: 
 Values are presented as Means ± SE (standard errors)  
 Significant           * (P<0.05) 
Highly significant   ** (P<0.01)    
  Groups: 
(A): fed normal diet only. 
 (B): fed 1%cholesterol diet. 
(C): fed 1%cholesterol diet &received 10 mg/kg Simvastatin. 
(D): fed 1%cholesterol diet & received 40 mg/kg Simvastatin. 
(E): fed 1%cholesterol diet & received 80 mg/kg Simvastatin. 
Table (5): Mean changes in serum constituents in an induced 
hypercholeserolemic rats treated with Simvastatin: 
2 B 30.75±2.8 128.75±5.7 
 C 37.30±3.1 142.50±5.9 
 D 55.53±3.7* 134.00±5.8 
 E 46.93±3.4* 82.25±4.5* 
4  B 42.60±3.3 84.00±4.6 
 C 24.80±2.9* 94.33±5.6 
 D 38.60±3.1*    69.75±4.2*   
 E 13.83±2.1** 60.33±4.5*   
Period(weeks) Groups Urea Creatinine sodium potassium
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Values are presented as Means ± SE (standard errors)  
 Significance             *    (P<0.05)   
Highly significance **   (P<0.01) 
Groups: 
(A): control (fed normal diet only). 
 (B): fed cholesterol-containing diet 1% only. 
(C): fed cholesterol-containing diet 1% &received 10 mg/kg simvastatin. 
(D): fed cholesterol-containing diet 1%& received 40 mg/kg simvastatin. 
(E): fed cholesterol-containing diet 1%& received 80 mg/kg simvastatin. 
 
2 B 43.25±3.3 0.7±0.43 147±8.6 6.6±1.8 
 C 50.00±3.5 0.7±0.43 144±12 7.1±2.7 
 D 45.00±3.4 0.7±0.43 146±12 5.1±2.3 
 E 49.25±3.5 0.7±0.42 152±12.3 7.3±2.7 
4 B 58.50±3.8 0.7±0.4 138.75±5.9 10.3±2.3 
 C 46.00±3.9*   0.8±0.4 131±6.6 8.9±2.1 
 D 42.25±3.3*   0.7±0.4 140±5.9 7.9±1.4 
 E 31.00±2.8**   0.5±0.4 138.67±6.8 8.5±1.7 
Period 
(Weeks) 
  Groups    RBCs 
(10mm6) 
WBCs      
(10mm3) 
   Hb  
 (g/dL) 
  PCV 
     (%) 
Platelets     
(mg/dL) 
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Table (6): Mean changes in hematological parameters in an induced 
hypercholeserolemic rats treated with   Simvastatin: 
 
Values are presented as Means ± SE (standard errors)  
 Significance             *    (P<0.05)    
Groups: 
(A): control (fed normal diet only). 
 (B): fed 1% cholesterol diet only. 
(C): fed 1% cholesterol diet &received 10 mg/kg simvastatin. 
(D): fed 1% cholesterol diet & received 40 mg/kg simvastatin. 





4 B 6.7525±1.3 15.700±2.0 11.450±1.7 38.48±3.1 878.75±14.8
 C 5.8066±1.4 16.733±2.4 11.033±1.9 36.53±3.5 935.33±17.7
 D 4.8675±1.1 8.100±1.4* 9.425±1.5 30.43±2.8 694.25±13.2






Figure (3): Aorta from rats received 1%cholesterol diet. Notice 
thickness of the aortal wall, with precipitation of cholesterol clefts. 













Figure (4): kidney from rats received 1%cholesterol diet. Notice the 












Figure (5): Intestine from rats received 10mg/kg Bwt simvastatin. 
Notice the necrosis of the epithelial cells, increasing number of the 









Figure (6): kidney from rats received 40mg/kg Bwt simvastatin. Notice 
hemorrhage, segmented golmeruli, and infiltration of inflammatory 












Figure (7): Brain from rats received 80mg/kg Bwt simvastatin. Notice 
vaculation, demyelation of neurons, congestion and infiltration of 




Figure (7): Brain from rats received 80mg/kg Bwt simvastatin. Notice 
vaculation, demyelation of neurons, congestion and infiltration of 




Figure (8): The effect of feeding 1% cholesterol diet in plasma (Total 
cholesterol and Low Density Lipoprotein) in albino rats for two weeks: 
Groups: 
(A): fed normal diet: control  
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Figure (9): The effect of oral administration of Simvastatin in plasma 
(Total-cholesterol, LDL-c, HDL-c and triglycerides) in an induced 





















(A): fed normal diet: control.  
(B): fed 1%cholesterol diet.  
(C): fed 1%cholesterol diet & received simvastatin 10mg /kg Bwt. 
(D): fed 1%cholesterol diet & received simvastatin 40mg /kg Bwt. 






Figure (10): The effect of oral administration of Simvastatin in plasma (T.C, 
LDL, HDL and Triglycerides) in an induced hypercholesterolemic rats after 
4 weeks: 
Groups: 
(A): fed normal diet: control  
(B): fed 1%cholesterol diet  
 (C): fed 1%cholesterol diet & received simvastatin 10mg /kg Bwt 
(D): fed 1%cholesterol diet & received simvastatin 40mg /kg Bwt 





















Figure (11): The effect of oral administration of simvastatin in (Blood Urea 




















(A): fed normal diet: control  
(B): fed 1%cholesterol diet  
 (C): fed 1%cholesterol diet & received simvastatin 10mg /kg Bwt 
(D): fed 1%cholesterol diet & received simvastatin 40mg /kg Bwt 







Figure (12): The effects of oral administration of Simvastatin in serum 












 (A): fed normal diet: control  
(B): fed cholesterol-containing diet 1% 
(C): fed cholesterol-containing diet 1% & simvastatin 10mg /kg Bwt 
(D): fed cholesterol-containing diet 1%& simvastatin 40mg /kg Bwt 


























4.1 Induction of hypercholesterolemia and body weight: 
  In this study, the addition of 1%cholesterol in diet for 2weeks 
significantly increase rat’s body weight, and plasma cholesterol to level 
up to 193.33 mg/dL, this finding is on line with Hwancheol et al., (2004) 
who found that, hypercholesterolemia can be induced on Wistar rats when 
they were fed a diet supplemented with cholesterol, the plasma cholesterol 
and body weight were significantly elevated in rats received a 1% 
cholesterol diet for 8 weeks. Also Getz et al., (2006) found that, Lipid-
enriched diets are often used to induce or accelerate the rate of 
induction of persistent hypercholesterolemia in mice to levels > or 
approximately 300 mg/dL, as well as the protein source has been shown 
to influence lipoprotein level. 
Birkner et al., (2009) showed that experimental hypercholesterolemia 
has been induced in the animals with the diet enriched with 0.5 and 2 
g% of cholesterol/100 g of fodder/24 hours. 
4.2 lipid profiles: 
4.2.1 Total cholesterol (T.C): 
 In this study, Simvastatin had a  hypocholesterolemic effect in  
treated groups with 10, 40, 80mg\kg Bwt, it reduced cholesterol by 
24.75% , 31.34%, 93.46%, respectively ,this agreed with Ragino et al., 
(2008)  who used rabbit model of experimental hypercholesterolemia, 
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he found that the hypocholesterolemic effect of Simvastatin in doses of 
40, 66.5, and 100 mg/kg/day  on  total blood cholesterol  decreased by  
39,  36, 47, and 38% (p < 0.05), respectively, after 20-days course of 
the preparation. On the other hand, Fraunberger ,(2008) found that 
simvastatin reduced circulating total-cholesterol and LDL- cholesterol levels 
by 68 % and 76 %, respectively. 
4.2.2 Low density lipoproteins 
 The current study, showed that simvastatin had a significant 
effect on LDL-c (0.05), this result is on line with the result of 
Ballantyne et al., (2008) who found that treatment with simvastatin 
significantly (p<0.05) reduced total cholesterol, total triglycerides and low-
density lipoprotein cholesterol (LDL-C), statin therapy alters the 
relationship between apolipoprotein B and low-density lipoprotein 
cholesterol and non-high-density lipoprotein cholesterol targets in high-
risk patients. 
 Youssef et al., (2004) also demonstrated that there was a significant 
reduction (P<0.0001) in Total-cholesterol from (6.6 ±1.0 to 5.2± 0.8) 
mmol/L and LDL-cholesterol from (4.3 ±1.0 to 2.8 ±0.7) mmol/L following 
the use of simvastatin.  
4.2.3 High density lipoproteins 
The present study showed that, Simvastatin treatment had no 
effect on HDL-c. This result is in agreement with that of  Bryan et al., 
(2005) who found that, the use of statins is effective against high levels 
of LDL- c, it has little or no effect in raising HDL-c .However, 
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McTaggar and Jones, (2008) demonstrated that, Statins cause modest 
increases in HDL-C and apo A-I probably mediated by reductions in  
cholesteryl ester transfer protein CETP activity, The most likely 
explanation is a reduced rate of (CETP)-mediated flow of cholesterol 
from HDL. McTaggar and Jones, (2008) found that the Statin effects on 
HDL reduce progression of atherosclerosis and risk of cardiovascular 
disease independently of reductions in LDL. 
Pirat et al, (2004) found that, when comparing their results with baseline 
values, HDL-C values significantly increased (p<0.05) when 20mg\kg 
Simvastatin therapy was used.  
4.2.4Triglycerides 
This study found that Simvastatin had a slight effect on 
Triglycerides level and this agree with Ellen and Mcpherson, (1998). 
Who found that, combination treatment with fenofibrate and low-dose 
Simvastatin is generally safe and effective for the treatment of 
combined hyperlipidemia (in which there is elevation in serum 
cholesterol and triglycerides together) in patients with normal hepatic 
and renal function. 
Youssef et al., (2004) found that significant reduction occurred in the high-





4.3 Renal profile: 
4.3.1 Blood Urea: 
Simvastatin which are effective lipid lowering drugs also possess 
anti-inflammatory potential. However, circulating lipoproteins may also 
play a protective role during acute inflammatory diseases due to their 
ability to bind bacterial toxins. Fraunberger, (2008) found that 
Simvastatin which drastically reduce circulating cholesterol levels 
should be beneficial in patients with inflammatory diseases who are 
already hypocholesteremic. In the current study Simvastatin 
significantly decreases blood urea level. These findings were in line 
with Zhang et al., (2008) who found that Simvastatin treatment 
significantly decreased renal function test and prevented 
glomerulosclerosis independent of the lipid-lowering effects. This 
beneficial effect of Simvastatin might be mediated by its anti-
inflammatory activity.  
4.4 Histopathological findings: 
In the present study, simvastatin caused infiltration of microglial cells 
in the brain of rats treated with 80mg/kg Bwt, this finding agreed with that 
of Bi X et al., (2004) who found that simvastatin caused a concentration- 
and time-dependent activation of microglia in cultured rat hippocampus 
slices. This response consisted of a transformation of the cells from a typical 
resting configuration to an amoeboid, macrophage-like morphology, 
increased expression of a macrophage antigen, and up-regulation of the 
cytokine tumor necrosis factor-alpha. Evidence for proliferation was also 
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obtained. Statin-induced microglial changes were blocked by mevalonate but 



















In this study, it is confirmed that Simvastatin possesses a potent effect 
on Serum cholesterol and LDL-cholesterol and had undesirable effects on 
renal system when it was given in high doses for along period of time “dose 
dependent”  
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